The Medical Treatments of Intestinal Behçet's Disease: An Update

장염은 염증성 장질환과 유사한 임상 경과를 보인다. 이렇게 특별히 위장관 증상이 뚜렷하고 내시경이나 방사선 소견 등 객관적인 검사에 서 장에 전형적인 궤양성 병변이 있다면 “베체트 장염”이라고 정의할 수 있다(Fig. 1). 베체트 장염이 중요한 이유는 장 침범은 종종 장천공이나 대량출 혈과 같은 심각한 합병증을 초래할 수 있고 사망의 주원인이 될 수 있 기 때문이다. 하지만 베체트 장염은 흔한 질환이 아니므로 치료에 대 한 관심과 이해가 상대적으로 적어, 베체트 장염의 치료방법 및 임상 경과, 예후 예측인자에 대해 아직까지 자세한 연구가 부족한 상황이 고 표준화된 치료 약제나 그 효과에 대해 정확한 평가가 쉽지 않았 다. 특히 정확한 진단과 질병활성도를 객관적으로 측정할 수 있는 도 구가 개발되지 않아 임상연구에 이용할 수 없는 한계가 있었다. 최근 장연구학회 IBD 연구회에서 다기관 연구로 비교적 객관적인 진단기 준과 질병활성도지수를 개발하였고, 국내외 단일기관 또는 다기관 연 구를 통해 기존 사용 약제와 새로운 생물학 제제 등을 이용한 결과들 이 나오면서 베체트 장염을 위한 새로운 치료 형태의 패러다임이 형성 되고 염증성 장질환과 마찬가지로 치료 방법에 관심을 받기 시작했 다. 따라서 이 종설에서는 최근 발표된 치료 및 치료 반응에 관련된 예 후인자에 대한 논문들을 바탕으로 베체트 장염의 최신 내과적 치료에 The Medical Treatments of Intestinal Behcet’s Disease: An Update

[1]  J. S. Kim,et al.  Efficacy of Infliximab in Intestinal Behçet’s Disease: A Korean Multicenter Retrospective Study , 2013, Inflammatory bowel diseases.

[2]  G. Lichtenstein,et al.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. , 2013, World journal of gastroenterology.

[3]  Y. Jung,et al.  Long-term Clinical Outcomes of Crohn's Disease and Intestinal Behcet's Disease , 2013, Inflammatory bowel diseases.

[4]  Y. Jung,et al.  Clinical Course of Intestinal Behcet’s Disease During the First Five Years , 2013, Digestive Diseases and Sciences.

[5]  H. Ogata,et al.  A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. , 2012, Internal medicine.

[6]  Y. Jung,et al.  Long-Term Clinical Outcomes and Factors Predictive of Relapse After 5-Aminosalicylate or Sulfasalazine Therapy in Patients With Intestinal Behcet Disease , 2012, Journal of clinical gastroenterology.

[7]  Y. Jung,et al.  Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease , 2012, Inflammatory bowel diseases.

[8]  S. R. Dalvi,et al.  Behcet’s Syndrome , 2012, Drugs.

[9]  Young Sook Park,et al.  Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet's disease , 2011, Inflammatory bowel diseases.

[10]  M. Chung,et al.  Response Rates to Medical Treatments and Long-term Clinical Outcomes of Nonsurgical Patients With Intestinal Behçet Disease , 2010, Journal of clinical gastroenterology.

[11]  T. Kim,et al.  Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal Behcet's Disease: Pilot Experience in a Single Center , 2010 .

[12]  T. Chiba,et al.  Efficacy of oral tacrolimus on intestinal Behcet's disease. , 2010, Inflammatory bowel diseases.

[13]  T. Kim,et al.  Prediction of Free Bowel Perforation in Patients with Intestinal Behçet’s Disease Using Clinical and Colonoscopic Findings , 2010, Digestive Diseases and Sciences.

[14]  C. Berkelhammer,et al.  Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy. , 2009, Inflammatory bowel diseases.

[15]  Eun Soo Kim,et al.  Development and Validation of Novel Diagnostic Criteria for Intestinal Behçet's Disease in Korean Patients With Ileocolonic Ulcers , 2009, The American Journal of Gastroenterology.

[16]  J. Valente,et al.  Behçet's disease--a contemporary review. , 2009, Journal of autoimmunity.

[17]  E. Ebert Gastrointestinal Manifestations of Behçet’s Disease , 2009, Digestive Diseases and Sciences.

[18]  H. Ogata,et al.  Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease , 2008, Inflammatory bowel diseases.

[19]  T. Yamazaki,et al.  Thalidomide for treatment of intestinal involvement of juvenile‐onset Behçet disease , 2008, Inflammatory bowel diseases.

[20]  K. Takenaka,et al.  Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by up-front cord blood transplantation. , 2007, Internal medicine.

[21]  T. Matsui,et al.  Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach , 2007, Journal of Gastroenterology.

[22]  C. Lee,et al.  [Pathogenesis and treatment of intestinal Behçet's disease]. , 2007, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[23]  S. Ohno,et al.  Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. , 2007, Rheumatology.

[24]  T. Missotten,et al.  Adalimumab: a new modality for Behçet’s disease? , 2006, Annals of the rheumatic diseases.

[25]  S. Shin,et al.  Anti-Saccharomyces cerevisiae Antibody in Intestinal Behçet’s Disease Patients: Relation to Clinical Course , 2006, Diseases of the colon and rectum.

[26]  I. Olivieri,et al.  New approaches in the treatment of Adamantiades-Behçet's disease , 2006, Current opinion in rheumatology.

[27]  C. Evereklioglu,et al.  Current concepts in the etiology and treatment of Behçet disease. , 2005, Survey of ophthalmology.

[28]  Gabriele Rossi,et al.  Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. , 2004, Blood.

[29]  Y. Akova,et al.  Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. , 2003, Rheumatology.

[30]  M. Kurihara,et al.  Endoscopic therapy with absolute ethanol for postoperative recurrent ulcers in intestinal Behçet's disease, and simple ulcers , 2001, Journal of Gastroenterology.

[31]  I. Choi,et al.  Prediction of the clinical course of Behçet's colitis according to macroscopic classification by colonoscopy. , 2000, Endoscopy.

[32]  J. S. Kim,et al.  Long-term clinical course and prognostic factors in intestinal Behçet's Disease , 2000, Diseases of the colon and rectum.

[33]  A. Okada Drug therapy in Behçet's disease , 2000, Ocular immunology and inflammation.

[34]  Y. Ozyazgan,et al.  Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome , 1998, Annals of Internal Medicine.

[35]  J. Kang,et al.  Clinical Features of Intestinal Behoet's Disease and Therapeutic Effects of Sulfasalazine , 1997 .

[36]  H. Larsson Treatment of severe colitis in Behcet's syndrome with thalidomide (CG‐217) , 1990, Journal of internal medicine.

[37]  J. O'duffy Behcet's disease. , 1981, Minnesota medicine.

[38]  J. Carney,et al.  Behçet's Disease: Report of 10 Cases, 3 with New Manifestations , 1971 .